信达生物(01801)绩后高开近4%，截至发稿，涨3.97%，报40.6港元，成交额2094.96万港元。

消息面上，3月26日，信达生物公布2024年业绩，收入约94.22亿元，同比增长51.8%。毛利约79.12亿元，同比增长56.1%。年内亏损9463.1万元，同比收窄90.8%。

其中，产品收入为82.28亿元，同比增长43.6%。强劲的业绩表现主要得益于公司在肿瘤领域的领先地位，达伯舒® (信迪利单抗注射液)在内的主要产品保持收入的强劲增长，叠加新产品的快速放量。授权费收入为约11亿元，较2023年度的4.47亿元有所增长，进一步推动报告期内总收入增长。

2024年财务业绩的大幅提升主要来自：高速的收入增长，包括强劲的产品收入增长势头和授权费收入的增加；以及运营效率的持续改善，包括产品生产成本的进一步优化，销售和营销活动效率和生产力及管理职能效率的进一步提升。

海量资讯、精准解读，尽在新浪财经APP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.